Skip to content

The Role and Intervention of TGF-β in Abdominal Radiation Injury

The Role of TGF-β in Abdominal Radiation Injury and Taking Medicine to Block TGF-β for Protecting Normal Organization

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03613506
Enrollment
226
Registered
2018-08-03
Start date
2019-10-25
Completion date
2022-12-25
Last updated
2022-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radiotherapy Side Effect, Taking Captopril

Brief summary

This project aims to investigate the relationship between radiation-induced the relationship between elevated peripheral blood TGFβ and complications of radiotherapy,and to analysis of changes in peripheral blood TGFβ levels after abdominal radiotherapy and its relationship with radiotherapy complications.Simultaneously,Patients who underwent abdominal radiotherapy were given captopril (sustained release) to block TGFβ,Whether it can reduce peripheral blood TGFβ levels and reduce radiotherapy complications,to explore the protective effect of blocking TGFβ secretion on normal tissues after radiotherapy.

Interventions

Taking captopril 12.5mg b.i.d for two months before radiotherapy.

Sponsors

Wuhan University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Informed consent form for this study has been signed 2. Age 18-70 years old, gender is not limited,Pathological diagnosis of patients with advanced malignant tumors,Radiotherapy indications; 3. BED (α/β=10)≥50;ECOG score 0-2;Blood routine:WBC≥3.5×109/L,GRAN≥2.0×109/L,Hb≥90g/L,PLT≥100×109/L; 4. Liver function: ALT or AST ≤ 2.5 times the normal high value (ULN);Bilirubin ≤ 1.5 × ULN, serum APK ≤ 2.5 × ULN; 5. Renal function:Serum creatinine ≤1.5×ULN, and creatinine clearance ≥60ml/min 6. No organ transplant history 7. Women of childbearing age must undergo a urine pregnancy test within 7 days prior to initiation of treatment and the results are negative and not in lactation 8. Male and female patients of childbearing age agreed to adopt a reliable method of contraception before entering the trial and during the study until 30 days after stopping the drug.

Exclusion criteria

1. Patients undergoing chemotherapy or targeted therapy at the same time 2. Long-term use of ACEI or ARB drugs for hypertension 3. This radiotherapy site has been treated with radiotherapy;Combined with severe heart disease or major organ failure 4. Have a history of drug abuse or alcohol addiction 5. Combined active infection 6. Combined with severe malnutrition or severe anemia 7. Human immunodeficiency virus (HIV) infection 8. During pregnancy or lactation 9. Those who are unable to tolerate or may be allergic to the drugs used in this study;Persons without civil capacity or limited capacity for civil conduct; 10. Researchers believe that it is not suitable for inclusion

Design outcomes

Primary

MeasureTime frameDescription
Study the effect of abdominal radiation therapy on peripheral blood TGFβ levels12 weeksThe levels of TGF-β in peripheral blood of patients before and after radiotherapy were compared.
Blocking TGFβ for protective effect on normal tissues12 weeksGive two groups of patients captopril (sustained release) 12.5mg b.i.d. for two months,comparing their levels of TGF-β in peripheral blood

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026